Group 1 - Centessa Pharmaceuticals plc announced an upsized underwritten public offering of 15,254,237 American Depositary Shares (ADSs) at a price of $14.75 per ADS, expecting gross proceeds of approximately $225 million before expenses [1] - The offering is expected to close on or about September 16, 2024, subject to customary closing conditions, and underwriters have a 30-day option to purchase an additional 2,288,135 ADSs [1] - The ADSs are being offered under a registration statement filed with the SEC on September 11, 2024, which became effective upon filing [3] Group 2 - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [2] - Centessa Pharmaceuticals focuses on discovering and developing transformational medicines, with advanced programs in hemophilia, narcolepsy, and immuno-oncology [5]

BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to pur ...

2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT) Favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, visual disturbances or hepatotoxicity as of the data cutoff date 1 PK profile supports once-daily dosing Company plans to rapidly initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1 (NT1), narcolepsy ty ...

BOSTON and LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a latebreaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40445 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98- ...

Exhibit 99.1 Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 • Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists – Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and ef icacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 – Nominated ORX142 as development candidate; Currently in IND enabl ...

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) ...

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than ...

Executive Leadership Changes - John Crowley CPA has been appointed as the new Chief Financial Officer (CFO) of Centessa Pharmaceuticals, bringing over 20 years of global finance and operational experience in the life sciences industry [5][9] - Gregory Weinhoff MD MBA, the former CFO, has been appointed to the newly created role of Chief Business Officer (CBO), leveraging his extensive business development experience [5][6] - John Crowley's previous roles include CFO at Fusion Pharmaceuticals, Executive Vice President and CFO at Merus Inc, and senior corporate finance positions at Charles River Laboratories, Ironwood Pharmaceuticals, Vertex Pharmaceuticals, and Sunovion Pharmaceuticals [9] - Gregory Weinhoff has over 20 years of business development experience, including roles as CFO at Centessa and Axovant Sciences, and co-founder of Arvelle Therapeutics, which was acquired by Angelini Pharma in 2021 [3] Company Overview and Strategic Focus - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients [7] - The company's most advanced programs include a hemophilia program, an orexin agonist program for narcolepsy and sleep-wake disorders, and an immuno-oncology program based on the LockBody® technology platform [7] - The company believes its programs have the potential to change current treatment paradigms and establish new standards of care [7] - Centessa has strengthened its leadership team to position the company for its next phase of growth, with a focus on advancing its clinical programs and maintaining a strong financial framework [1] Business Development and Financial Strategy - The appointment of John Crowley as CFO is expected to enhance the company's financial strategy, operations, and planning, given his deep technical knowledge and experience in the life sciences industry [1][9] - Gregory Weinhoff's new role as CBO will focus on leveraging his experience in developing strategic industry partnerships to bring transformative medicines to patients [6] - The company has emphasized the importance of business development and financial strategy as it transitions into its next chapter of growth [1][6]

Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) has been beaten down lately with too much selling pressure. While the stock has lost 11% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This ...